Meningococcal Vaccine Market
Meningococcal Vaccine Market Study by Polysaccharide Vaccines (MPSV4), Conjugate Vaccines (MCV4), and Serogroup B Vaccines (MenB-FHpb/MenB-4C) from 2024 to 2034
Analysis of Meningococcal Vaccine Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Meningococcal Vaccine Market Outlook (2024 to 2034)
The global meningococcal vaccine market is expected to develop at a CAGR of 10.3% from 2024 to 2034. The market is estimated to be valued at US$ 4,049.1 million in 2024. Sales of meningococcal vaccines are expected to reach US$ 10,788.0 million by 2034.
The market is fueled by the prevalence of meningococcal illnesses, particularly meningococcal meningitis, which are extremely contagious among people or groups. The growing cases of these diseases are driving the need for meningococcal vaccination. The rising emphasis on preventive healthcare is also stimulating market demand.
Key Market Growth Drivers
- The demand for meningococcal vaccination is widespread and complicated, with 29 approved vaccines targeting combinations of the six serogroups (A, B, C, W, X, and Y) and geographical differences in serogroup distribution.
- Significant usage outside normal vaccination, such as subnational use, immunization of specific risk groups such as military personnel or tourists, use in the private sector, or recommended but unreimbursed immunization, drives the market for meningococcal vaccines.
- The market is progressing as meningococcal polysaccharide vaccines (MPSV) and meningococcal polysaccharide-protein conjugated vaccines (MCV) are the only available vaccines for invasive meningococcal illnesses.
- Government investments in meningococcal vaccinations are driven by meningococcal outbreaks, increasing the demand for vaccines. The illness, particularly meningococcal meningitis, is a public health concern due to high fatality rates and long-term neurological abnormalities in babies and children.
The global market for meningococcal vaccines is anticipated to grow over the forecast period due to a strong product pipeline. The sector is expected to expand progressively over the decade as more innovative and effective solutions are being developed and made publicly accessible.
| Report Attributes | Details |
|---|---|
| Estimated Market Value (2024E) | US$ 4,049.1 million |
| Forecasted Market Value (2034F) | US$ 10,788.0 million |
| Global Market Growth Rate (2024 to 2034) | 10.3% CAGR |
| Meningococcal Conjugate Vaccine (MCV4) Segment Growth Rate (2024 to 2034) | 10.4% |
| Adolescents and Young Adults Segment Growth Rate (2024 to 2034) | 9.8% |
| North America Market Share (2024) | 55.3% |
| East Asia Market Share (2024) | 7.2% |
| Key Companies Profiled | Incepta Pharmaceuticals Limited; Novartis International; GlaxoSmithKline plc; Merck; CSL; Baxter International; JN International Medical Corporation; Serum Institute of India; Biomed Pvt. Ltd; China National Biotec Group; Hualan Biological Engineering Inc.; Walvax Biotechnology Co., Ltd.; Zhifei; Pfizer Inc.; GlaxoSmithKline plc.; Sanofi SA; Nuron Biotech |
Don't Need a Global Report?
save 40%! on Country & Region specific reports
Which Facets are Driving the Global Surge in Meningococcal Vaccine Demand?
“Rising Prevalence of Meningitis”
The rising cases of cerebrospinal meningitis, often known as bacterial meningitis, can cause death or lifelong disability. This is boosting the market’s growth. Long-term consequences of bacterial meningitis include learning difficulties, brain damage, hearing loss, memory loss, and even septicemia.
Some factors are anticipated to drive the prospects for market expansion, including the increasing incidence of meningitis in children, the growing need for a permanent treatment for meningitis, and the collaboration between the public and private sectors to support vaccination programs.
Organizations such as the Commonwealth and BRICS are developing and producing meningococcal vaccines. This is an excellent opportunity for giant corporations to get involved in vaccine research and development.
“Growing Focus on Research and Development Driving Market Growth”
The growth in the meningococcal vaccine market is expected to accelerate globally with the presence of international pharmaceutical companies, healthcare facilities, and non-profit organizations that support research projects, train healthcare professionals, and provide information & assistance to patients.
The commercialization of the vaccines is predicted to fuel the expansion of the meningitis vaccine market, creating lucrative opportunities for several industry participants.
These pharmaceutical companies support ongoing research and innovative methods of illness prevention. Therefore, these factors are expected to drive the rise of the meningococcal vaccine market during the forthcoming decade.
What are the Challenges Encountered by Meningococcal Vaccine Manufacturers?
“Limited Vaccine Supply Restricts the Meningococcal Vaccine Market Growth”
The limited global availability of polysaccharide vaccines and the high cost of conjugate vaccines hinder access to multivalent and conjugate vaccinations for low-income countries (LICs) and middle-income countries (MICs).
This lack of resources makes meningitis vaccinations less accessible to disadvantaged communities and makes it more difficult to distribute them equitably.
The financial limitations of these countries, in addition to their restricted accessibility, act as a major barrier to the expansion of the meningitis vaccination industry globally.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Country-wise Insights
The meningitis vaccine market in North America is projected to expand at an 11.1% CAGR through 2034. In 2024, the United States is predicted to dominate the North American meningococcal vaccine market with a 92.5% market share.
Meanwhile, East Asia's meningococcal vaccine industry is projected to grow at a CAGR of 9.8% through 2034. In 2024, meningitis vaccines are estimated to account for 59.1% of China's industry.
Why is the United States Dominating the Global Meningococcal Vaccine Market?
“Rigid Healthcare Infrastructure in the United States Driving Market Demand”
| Attribute | Details |
|---|---|
| Market Value (2024) | US$ 2,071.3 million |
| CAGR (2024 to 2034) | 11.2% |
The demand for meningococcal vaccination in the United States is expected to increase and reach a predicted value of US$ 2,071.3 million in 2024. In the North American meningitis vaccine market, the United States is expected to command a 92.5% share in 2024. The market is projected to grow at an 11.2% CAGR from 2024 to 2034.
Over the projection period, the meningococcal vaccine market is anticipated to grow due to the expansion of the United States’ healthcare sector and the growing number of vaccination and innovative medicine approvals from the FDA.
The sophisticated healthcare system in the United States and the emphasis on vaccinations mean that timely delivery will further support the market's growth. The market for meningococcal vaccines in the United States is thus expected to grow over the projected period.
Which Aspect Positions China as a Prospering Meningococcal Vaccine Industry?
“Growing Government Initiatives Propelling the Chinese Meningococcal Vaccination Sector”
| Attribute | Details |
|---|---|
| Market Value (2024) | US$ 173 million |
| CAGR (2024 to 2034) | 10.0% |
The demand for meningococcal vaccines is expected to increase considerably in China, with an estimated market value of US$ 173 million in 2024. Moreover, the projected CAGR during the forecast period is 10.0%, which is quite promising. This anticipated growth is expected to result in a market value of US$ 451 million by 2034.
Sales of meningococcal vaccinations are rising in China due to increased government efforts to curb the spread of diseases and an increase in the number of children under 18 years of age. Non-profit organizations in China also disseminate information to the public and increase awareness among medical professionals. Furthermore, more people are expected to receive the meningococcal vaccines.
The rise in significant government support, recommendations, and substantial funding for research and development is fueling growth in the market. More awareness campaigns and a sophisticated healthcare system in China are anticipated to support market expansion. Attendees of the meningococcal vaccine market also participate in a campaign to increase vaccination rates and spread awareness of the disease.
Category-wise Insights
The meningococcal conjugate vaccine (MCV4) segment is expected to hold a 41.6% market share by product type in 2024. Simultaneously, the serogroup B meningococcal vaccine (MenB-FHpb/MenB-4C) segment is expected to secure 35.3% of the market, significantly enhancing the industry's resource diversity and stability.
Based on age, adolescents and young adults are expected to have a substantial 28.4% share in the meningococcal vaccination market in 2024. The market share of children aged from 2 to 12 years is anticipated to hold 25.5% of the market in 2024.
Why is the Demand for Meningococcal Conjugate Vaccines (MCV4) Amplifying?
“Meningococcal Conjugate Vaccine Promotes Herd Immunity”
| Attribute | Details |
|---|---|
| Market Share in 2024 | 41.6% |
In 2024, meningococcal conjugate vaccines are expected to hold a 41.6% market share. The MCV4 shots category is anticipated to increase at a CAGR of 10.4% over the following decade. The meningococcal conjugate vaccine (MCV4) vaccination demand is expected to be valued at US$ 1,684.2 million in 2024.
To enhance the immune system's response to the weak antigen, a meningococcal conjugate vaccination mixes a weak antigen with a powerful antigen as a carrier. Due to its main benefits, including the capacity to create herd immunity and provide long-lasting protection, the MCV4 sector of the meningococcal vaccine market is expanding.
The meningococcal conjugate vaccine (MCV4) segment is predicted to develop rapidly throughout the projection period because of major benefits such as long-lasting protection and the capacity to promote herd immunity.
Additionally, several major players are developing different meningococcal conjugate vaccination solutions, which present opportunities for the meningitis vaccine market to expand.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Competitive Landscape
The key players in the meningococcal vaccine market include Incepta Pharmaceuticals Limited, Novartis International, GlaxoSmithKline plc, Merck, CSL, Baxter International, JN International Medical Corporation, Serum Institute of India, Biomed Pvt. Ltd, China National Biotec Group, Hualan Biological Engineering Inc., Walvax Biotechnology Co., Ltd., Zhifei, Pfizer Inc., GlaxoSmithKline plc., Sanofi SA, and Nuron Biotech.
The global meningococcal vaccination industry is growing quickly and is a very competitive market where many companies are vying for market share and a solid foundation. Several elements, including price tactics, marketing campaigns, research and development, and innovative product creation, drive market competition.
Due to the considerable fragmentation of the meningitis vaccine market and the competition among the companies for market share, there is a greater emphasis on strategic decision-making and competitive pressures. Players are aggressively spending on research and development to create new, more potent vaccines to stay ahead of the competition.
To increase operational effectiveness and expand market reach, partnerships, collaborations, and other strategic alliances are also being developed. Companies also use product releases and other marketing campaigns to enhance meningitis vaccine sales and obtain a competitive advantage.
Recent Developments
- In December 2023, Pfizer announced the FDA approval of Penbraya, the first pentavalent vaccine for meningococcal disease in individuals aged 10-25, providing enhanced protection against serious and life-threatening infections in adolescents and young adults.
- In July 2023, the Serum Institute of India Private Limited developed MenFive, the first conjugate vaccine pre-qualified by the World Health Organization to protect against five major causes of meningococcal meningitis in Africa.
Segmentation of the Meningococcal Vaccine Market
-
By Product type :
- Meningococcal Polysaccharide Vaccine (MPSV4)
- Meningococcal Conjugate Vaccine (MCV4)
- Serogroup B Meningococcal Vaccine (MenB-FHpb/MenB-4C)
-
By Age Group :
- Infants (0-24 months)
- Children (2-12 years)
- Adolescents and young adults
- Adults
-
By Distribution Channels :
- Institutional Sales
- Retail Sales
-
By Region :
- North America
- Europe
- East Asia
- East Asia
- South Asia & Oceania
- Middle East & Africa
Table of Content
- 1. Executive Summary
- 2. Market Overview
- 3. Market Background
- 4. Global Market Analysis 2019 to 2023 and Forecast, 2024 to 2034
- 5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Type
- 5.1. Bivalent
- 5.2. Quadrivalent
- 5.3. Others
- 6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Brand
- 6.1. Menactra
- 6.2. Menveo
- 6.3. Nimenrix
- 6.4. Trumenba
- 6.5. Bexsero
- 6.6. Others
- 7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Age Group
- 7.1. Infants (0 to 2 years)
- 7.2. Children And Adults (2 years & above)
- 8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Serotype
- 8.1. Serotype A
- 8.2. Serotype B
- 8.3. Serotype C
- 8.4. Serotype W-135
- 8.5. Serotype Y
- 9. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By End-User
- 9.1. Hospitals
- 9.2. Pharmacy Stores
- 9.3. Others
- 10. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region
- 10.1. North America
- 10.2. Latin America
- 10.3. Western Europe
- 10.4. Eastern Europe
- 10.5. South Asia and Pacific
- 10.6. East Asia
- 10.7. Middle East and Africa
- 11. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
- 12. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
- 13. Western Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
- 14. Eastern Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
- 15. South Asia and Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
- 16. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
- 17. Middle East and Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
- 18. Key Countries Market Analysis
- 19. Market Structure Analysis
- 20. Competition Analysis
- 20.1. Sanofi SA
- 20.2. Novartis International
- 20.3. GlaxoSmithKline plc
- 20.4. Pfizer Inc.
- 20.5. Nuron Biotech
- 20.6. JN-International Medical Corporation
- 20.7. Serum Institute of India Ltd
- 20.8. Baxter International
- 20.9. Biomed Pvt. Ltd
- 21. Assumptions & Acronyms Used
- 22. Research Methodology
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 1: Global Market Value (US$ Million) Forecast by Region, 2019 to 2034
Table 2: Global Market Volume (Number of Doses) Forecast by Region, 2019 to 2034
Table 3: Global Market Value (US$ Million) Forecast by Type, 2019 to 2034
Table 4: Global Market Volume (Number of Doses) Forecast by Type, 2019 to 2034
Table 5: Global Market Value (US$ Million) Forecast by Brand, 2019 to 2034
Table 6: Global Market Volume (Number of Doses) Forecast by Brand, 2019 to 2034
Table 7: Global Market Value (US$ Million) Forecast by Age Group, 2019 to 2034
Table 8: Global Market Volume (Number of Doses) Forecast by Age Group, 2019 to 2034
Table 9: Global Market Value (US$ Million) Forecast by Serotype, 2019 to 2034
Table 10: Global Market Volume (Number of Doses) Forecast by Serotype, 2019 to 2034
Table 11: Global Market Value (US$ Million) Forecast by End-User, 2019 to 2034
Table 12: Global Market Volume (Number of Doses) Forecast by End-User, 2019 to 2034
Table 13: North America Market Value (US$ Million) Forecast by Country, 2019 to 2034
Table 14: North America Market Volume (Number of Doses) Forecast by Country, 2019 to 2034
Table 15: North America Market Value (US$ Million) Forecast by Type, 2019 to 2034
Table 16: North America Market Volume (Number of Doses) Forecast by Type, 2019 to 2034
Table 17: North America Market Value (US$ Million) Forecast by Brand, 2019 to 2034
Table 18: North America Market Volume (Number of Doses) Forecast by Brand, 2019 to 2034
Table 19: North America Market Value (US$ Million) Forecast by Age Group, 2019 to 2034
Table 20: North America Market Volume (Number of Doses) Forecast by Age Group, 2019 to 2034
Table 21: North America Market Value (US$ Million) Forecast by Serotype, 2019 to 2034
Table 22: North America Market Volume (Number of Doses) Forecast by Serotype, 2019 to 2034
Table 23: North America Market Value (US$ Million) Forecast by End-User, 2019 to 2034
Table 24: North America Market Volume (Number of Doses) Forecast by End-User, 2019 to 2034
Table 25: Latin America Market Value (US$ Million) Forecast by Country, 2019 to 2034
Table 26: Latin America Market Volume (Number of Doses) Forecast by Country, 2019 to 2034
Table 27: Latin America Market Value (US$ Million) Forecast by Type, 2019 to 2034
Table 28: Latin America Market Volume (Number of Doses) Forecast by Type, 2019 to 2034
Table 29: Latin America Market Value (US$ Million) Forecast by Brand, 2019 to 2034
Table 30: Latin America Market Volume (Number of Doses) Forecast by Brand, 2019 to 2034
Table 31: Latin America Market Value (US$ Million) Forecast by Age Group, 2019 to 2034
Table 32: Latin America Market Volume (Number of Doses) Forecast by Age Group, 2019 to 2034
Table 33: Latin America Market Value (US$ Million) Forecast by Serotype, 2019 to 2034
Table 34: Latin America Market Volume (Number of Doses) Forecast by Serotype, 2019 to 2034
Table 35: Latin America Market Value (US$ Million) Forecast by End-User, 2019 to 2034
Table 36: Latin America Market Volume (Number of Doses) Forecast by End-User, 2019 to 2034
Table 37: Western Europe Market Value (US$ Million) Forecast by Country, 2019 to 2034
Table 38: Western Europe Market Volume (Number of Doses) Forecast by Country, 2019 to 2034
Table 39: Western Europe Market Value (US$ Million) Forecast by Type, 2019 to 2034
Table 40: Western Europe Market Volume (Number of Doses) Forecast by Type, 2019 to 2034
Table 41: Western Europe Market Value (US$ Million) Forecast by Brand, 2019 to 2034
Table 42: Western Europe Market Volume (Number of Doses) Forecast by Brand, 2019 to 2034
Table 43: Western Europe Market Value (US$ Million) Forecast by Age Group, 2019 to 2034
Table 44: Western Europe Market Volume (Number of Doses) Forecast by Age Group, 2019 to 2034
Table 45: Western Europe Market Value (US$ Million) Forecast by Serotype, 2019 to 2034
Table 46: Western Europe Market Volume (Number of Doses) Forecast by Serotype, 2019 to 2034
Table 47: Western Europe Market Value (US$ Million) Forecast by End-User, 2019 to 2034
Table 48: Western Europe Market Volume (Number of Doses) Forecast by End-User, 2019 to 2034
Table 49: Eastern Europe Market Value (US$ Million) Forecast by Country, 2019 to 2034
Table 50: Eastern Europe Market Volume (Number of Doses) Forecast by Country, 2019 to 2034
Table 51: Eastern Europe Market Value (US$ Million) Forecast by Type, 2019 to 2034
Table 52: Eastern Europe Market Volume (Number of Doses) Forecast by Type, 2019 to 2034
Table 53: Eastern Europe Market Value (US$ Million) Forecast by Brand, 2019 to 2034
Table 54: Eastern Europe Market Volume (Number of Doses) Forecast by Brand, 2019 to 2034
Table 55: Eastern Europe Market Value (US$ Million) Forecast by Age Group, 2019 to 2034
Table 56: Eastern Europe Market Volume (Number of Doses) Forecast by Age Group, 2019 to 2034
Table 57: Eastern Europe Market Value (US$ Million) Forecast by Serotype, 2019 to 2034
Table 58: Eastern Europe Market Volume (Number of Doses) Forecast by Serotype, 2019 to 2034
Table 59: Eastern Europe Market Value (US$ Million) Forecast by End-User, 2019 to 2034
Table 60: Eastern Europe Market Volume (Number of Doses) Forecast by End-User, 2019 to 2034
Table 61: South Asia and Pacific Market Value (US$ Million) Forecast by Country, 2019 to 2034
Table 62: South Asia and Pacific Market Volume (Number of Doses) Forecast by Country, 2019 to 2034
Table 63: South Asia and Pacific Market Value (US$ Million) Forecast by Type, 2019 to 2034
Table 64: South Asia and Pacific Market Volume (Number of Doses) Forecast by Type, 2019 to 2034
Table 65: South Asia and Pacific Market Value (US$ Million) Forecast by Brand, 2019 to 2034
Table 66: South Asia and Pacific Market Volume (Number of Doses) Forecast by Brand, 2019 to 2034
Table 67: South Asia and Pacific Market Value (US$ Million) Forecast by Age Group, 2019 to 2034
Table 68: South Asia and Pacific Market Volume (Number of Doses) Forecast by Age Group, 2019 to 2034
Table 69: South Asia and Pacific Market Value (US$ Million) Forecast by Serotype, 2019 to 2034
Table 70: South Asia and Pacific Market Volume (Number of Doses) Forecast by Serotype, 2019 to 2034
Table 71: South Asia and Pacific Market Value (US$ Million) Forecast by End-User, 2019 to 2034
Table 72: South Asia and Pacific Market Volume (Number of Doses) Forecast by End-User, 2019 to 2034
Table 73: East Asia Market Value (US$ Million) Forecast by Country, 2019 to 2034
Table 74: East Asia Market Volume (Number of Doses) Forecast by Country, 2019 to 2034
Table 75: East Asia Market Value (US$ Million) Forecast by Type, 2019 to 2034
Table 76: East Asia Market Volume (Number of Doses) Forecast by Type, 2019 to 2034
Table 77: East Asia Market Value (US$ Million) Forecast by Brand, 2019 to 2034
Table 78: East Asia Market Volume (Number of Doses) Forecast by Brand, 2019 to 2034
Table 79: East Asia Market Value (US$ Million) Forecast by Age Group, 2019 to 2034
Table 80: East Asia Market Volume (Number of Doses) Forecast by Age Group, 2019 to 2034
Table 81: East Asia Market Value (US$ Million) Forecast by Serotype, 2019 to 2034
Table 82: East Asia Market Volume (Number of Doses) Forecast by Serotype, 2019 to 2034
Table 83: East Asia Market Value (US$ Million) Forecast by End-User, 2019 to 2034
Table 84: East Asia Market Volume (Number of Doses) Forecast by End-User, 2019 to 2034
Table 85: Middle East and Africa Market Value (US$ Million) Forecast by Country, 2019 to 2034
Table 86: Middle East and Africa Market Volume (Number of Doses) Forecast by Country, 2019 to 2034
Table 87: Middle East and Africa Market Value (US$ Million) Forecast by Type, 2019 to 2034
Table 88: Middle East and Africa Market Volume (Number of Doses) Forecast by Type, 2019 to 2034
Table 89: Middle East and Africa Market Value (US$ Million) Forecast by Brand, 2019 to 2034
Table 90: Middle East and Africa Market Volume (Number of Doses) Forecast by Brand, 2019 to 2034
Table 91: Middle East and Africa Market Value (US$ Million) Forecast by Age Group, 2019 to 2034
Table 92: Middle East and Africa Market Volume (Number of Doses) Forecast by Age Group, 2019 to 2034
Table 93: Middle East and Africa Market Value (US$ Million) Forecast by Serotype, 2019 to 2034
Table 94: Middle East and Africa Market Volume (Number of Doses) Forecast by Serotype, 2019 to 2034
Table 95: Middle East and Africa Market Value (US$ Million) Forecast by End-User, 2019 to 2034
Table 96: Middle East and Africa Market Volume (Number of Doses) Forecast by End-User, 2019 to 2034
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 1: Global Market Value (US$ Million) by Type, 2024 to 2034
Figure 2: Global Market Value (US$ Million) by Brand, 2024 to 2034
Figure 3: Global Market Value (US$ Million) by Age Group, 2024 to 2034
Figure 4: Global Market Value (US$ Million) by Serotype, 2024 to 2034
Figure 5: Global Market Value (US$ Million) by End-User, 2024 to 2034
Figure 6: Global Market Value (US$ Million) by Region, 2024 to 2034
Figure 7: Global Market Value (US$ Million) Analysis by Region, 2019 to 2034
Figure 8: Global Market Volume (Number of Doses) Analysis by Region, 2019 to 2034
Figure 9: Global Market Value Share (%) and BPS Analysis by Region, 2024 to 2034
Figure 10: Global Market Y-o-Y Growth (%) Projections by Region, 2024 to 2034
Figure 11: Global Market Value (US$ Million) Analysis by Type, 2019 to 2034
Figure 12: Global Market Volume (Number of Doses) Analysis by Type, 2019 to 2034
Figure 13: Global Market Value Share (%) and BPS Analysis by Type, 2024 to 2034
Figure 14: Global Market Y-o-Y Growth (%) Projections by Type, 2024 to 2034
Figure 15: Global Market Value (US$ Million) Analysis by Brand, 2019 to 2034
Figure 16: Global Market Volume (Number of Doses) Analysis by Brand, 2019 to 2034
Figure 17: Global Market Value Share (%) and BPS Analysis by Brand, 2024 to 2034
Figure 18: Global Market Y-o-Y Growth (%) Projections by Brand, 2024 to 2034
Figure 19: Global Market Value (US$ Million) Analysis by Age Group, 2019 to 2034
Figure 20: Global Market Volume (Number of Doses) Analysis by Age Group, 2019 to 2034
Figure 21: Global Market Value Share (%) and BPS Analysis by Age Group, 2024 to 2034
Figure 22: Global Market Y-o-Y Growth (%) Projections by Age Group, 2024 to 2034
Figure 23: Global Market Value (US$ Million) Analysis by Serotype, 2019 to 2034
Figure 24: Global Market Volume (Number of Doses) Analysis by Serotype, 2019 to 2034
Figure 25: Global Market Value Share (%) and BPS Analysis by Serotype, 2024 to 2034
Figure 26: Global Market Y-o-Y Growth (%) Projections by Serotype, 2024 to 2034
Figure 27: Global Market Value (US$ Million) Analysis by End-User, 2019 to 2034
Figure 28: Global Market Volume (Number of Doses) Analysis by End-User, 2019 to 2034
Figure 29: Global Market Value Share (%) and BPS Analysis by End-User, 2024 to 2034
Figure 30: Global Market Y-o-Y Growth (%) Projections by End-User, 2024 to 2034
Figure 31: Global Market Attractiveness by Type, 2024 to 2034
Figure 32: Global Market Attractiveness by Brand, 2024 to 2034
Figure 33: Global Market Attractiveness by Age Group, 2024 to 2034
Figure 34: Global Market Attractiveness by Serotype, 2024 to 2034
Figure 35: Global Market Attractiveness by End-User, 2024 to 2034
Figure 36: Global Market Attractiveness by Region, 2024 to 2034
Figure 37: North America Market Value (US$ Million) by Type, 2024 to 2034
Figure 38: North America Market Value (US$ Million) by Brand, 2024 to 2034
Figure 39: North America Market Value (US$ Million) by Age Group, 2024 to 2034
Figure 40: North America Market Value (US$ Million) by Serotype, 2024 to 2034
Figure 41: North America Market Value (US$ Million) by End-User, 2024 to 2034
Figure 42: North America Market Value (US$ Million) by Country, 2024 to 2034
Figure 43: North America Market Value (US$ Million) Analysis by Country, 2019 to 2034
Figure 44: North America Market Volume (Number of Doses) Analysis by Country, 2019 to 2034
Figure 45: North America Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 46: North America Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 47: North America Market Value (US$ Million) Analysis by Type, 2019 to 2034
Figure 48: North America Market Volume (Number of Doses) Analysis by Type, 2019 to 2034
Figure 49: North America Market Value Share (%) and BPS Analysis by Type, 2024 to 2034
Figure 50: North America Market Y-o-Y Growth (%) Projections by Type, 2024 to 2034
Figure 51: North America Market Value (US$ Million) Analysis by Brand, 2019 to 2034
Figure 52: North America Market Volume (Number of Doses) Analysis by Brand, 2019 to 2034
Figure 53: North America Market Value Share (%) and BPS Analysis by Brand, 2024 to 2034
Figure 54: North America Market Y-o-Y Growth (%) Projections by Brand, 2024 to 2034
Figure 55: North America Market Value (US$ Million) Analysis by Age Group, 2019 to 2034
Figure 56: North America Market Volume (Number of Doses) Analysis by Age Group, 2019 to 2034
Figure 57: North America Market Value Share (%) and BPS Analysis by Age Group, 2024 to 2034
Figure 58: North America Market Y-o-Y Growth (%) Projections by Age Group, 2024 to 2034
Figure 59: North America Market Value (US$ Million) Analysis by Serotype, 2019 to 2034
Figure 60: North America Market Volume (Number of Doses) Analysis by Serotype, 2019 to 2034
Figure 61: North America Market Value Share (%) and BPS Analysis by Serotype, 2024 to 2034
Figure 62: North America Market Y-o-Y Growth (%) Projections by Serotype, 2024 to 2034
Figure 63: North America Market Value (US$ Million) Analysis by End-User, 2019 to 2034
Figure 64: North America Market Volume (Number of Doses) Analysis by End-User, 2019 to 2034
Figure 65: North America Market Value Share (%) and BPS Analysis by End-User, 2024 to 2034
Figure 66: North America Market Y-o-Y Growth (%) Projections by End-User, 2024 to 2034
Figure 67: North America Market Attractiveness by Type, 2024 to 2034
Figure 68: North America Market Attractiveness by Brand, 2024 to 2034
Figure 69: North America Market Attractiveness by Age Group, 2024 to 2034
Figure 70: North America Market Attractiveness by Serotype, 2024 to 2034
Figure 71: North America Market Attractiveness by End-User, 2024 to 2034
Figure 72: North America Market Attractiveness by Country, 2024 to 2034
Figure 73: Latin America Market Value (US$ Million) by Type, 2024 to 2034
Figure 74: Latin America Market Value (US$ Million) by Brand, 2024 to 2034
Figure 75: Latin America Market Value (US$ Million) by Age Group, 2024 to 2034
Figure 76: Latin America Market Value (US$ Million) by Serotype, 2024 to 2034
Figure 77: Latin America Market Value (US$ Million) by End-User, 2024 to 2034
Figure 78: Latin America Market Value (US$ Million) by Country, 2024 to 2034
Figure 79: Latin America Market Value (US$ Million) Analysis by Country, 2019 to 2034
Figure 80: Latin America Market Volume (Number of Doses) Analysis by Country, 2019 to 2034
Figure 81: Latin America Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 82: Latin America Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 83: Latin America Market Value (US$ Million) Analysis by Type, 2019 to 2034
Figure 84: Latin America Market Volume (Number of Doses) Analysis by Type, 2019 to 2034
Figure 85: Latin America Market Value Share (%) and BPS Analysis by Type, 2024 to 2034
Figure 86: Latin America Market Y-o-Y Growth (%) Projections by Type, 2024 to 2034
Figure 87: Latin America Market Value (US$ Million) Analysis by Brand, 2019 to 2034
Figure 88: Latin America Market Volume (Number of Doses) Analysis by Brand, 2019 to 2034
Figure 89: Latin America Market Value Share (%) and BPS Analysis by Brand, 2024 to 2034
Figure 90: Latin America Market Y-o-Y Growth (%) Projections by Brand, 2024 to 2034
Figure 91: Latin America Market Value (US$ Million) Analysis by Age Group, 2019 to 2034
Figure 92: Latin America Market Volume (Number of Doses) Analysis by Age Group, 2019 to 2034
Figure 93: Latin America Market Value Share (%) and BPS Analysis by Age Group, 2024 to 2034
Figure 94: Latin America Market Y-o-Y Growth (%) Projections by Age Group, 2024 to 2034
Figure 95: Latin America Market Value (US$ Million) Analysis by Serotype, 2019 to 2034
Figure 96: Latin America Market Volume (Number of Doses) Analysis by Serotype, 2019 to 2034
Figure 97: Latin America Market Value Share (%) and BPS Analysis by Serotype, 2024 to 2034
Figure 98: Latin America Market Y-o-Y Growth (%) Projections by Serotype, 2024 to 2034
Figure 99: Latin America Market Value (US$ Million) Analysis by End-User, 2019 to 2034
Figure 100: Latin America Market Volume (Number of Doses) Analysis by End-User, 2019 to 2034
Figure 101: Latin America Market Value Share (%) and BPS Analysis by End-User, 2024 to 2034
Figure 102: Latin America Market Y-o-Y Growth (%) Projections by End-User, 2024 to 2034
Figure 103: Latin America Market Attractiveness by Type, 2024 to 2034
Figure 104: Latin America Market Attractiveness by Brand, 2024 to 2034
Figure 105: Latin America Market Attractiveness by Age Group, 2024 to 2034
Figure 106: Latin America Market Attractiveness by Serotype, 2024 to 2034
Figure 107: Latin America Market Attractiveness by End-User, 2024 to 2034
Figure 108: Latin America Market Attractiveness by Country, 2024 to 2034
Figure 109: Western Europe Market Value (US$ Million) by Type, 2024 to 2034
Figure 110: Western Europe Market Value (US$ Million) by Brand, 2024 to 2034
Figure 111: Western Europe Market Value (US$ Million) by Age Group, 2024 to 2034
Figure 112: Western Europe Market Value (US$ Million) by Serotype, 2024 to 2034
Figure 113: Western Europe Market Value (US$ Million) by End-User, 2024 to 2034
Figure 114: Western Europe Market Value (US$ Million) by Country, 2024 to 2034
Figure 115: Western Europe Market Value (US$ Million) Analysis by Country, 2019 to 2034
Figure 116: Western Europe Market Volume (Number of Doses) Analysis by Country, 2019 to 2034
Figure 117: Western Europe Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 118: Western Europe Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 119: Western Europe Market Value (US$ Million) Analysis by Type, 2019 to 2034
Figure 120: Western Europe Market Volume (Number of Doses) Analysis by Type, 2019 to 2034
Figure 121: Western Europe Market Value Share (%) and BPS Analysis by Type, 2024 to 2034
Figure 122: Western Europe Market Y-o-Y Growth (%) Projections by Type, 2024 to 2034
Figure 123: Western Europe Market Value (US$ Million) Analysis by Brand, 2019 to 2034
Figure 124: Western Europe Market Volume (Number of Doses) Analysis by Brand, 2019 to 2034
Figure 125: Western Europe Market Value Share (%) and BPS Analysis by Brand, 2024 to 2034
Figure 126: Western Europe Market Y-o-Y Growth (%) Projections by Brand, 2024 to 2034
Figure 127: Western Europe Market Value (US$ Million) Analysis by Age Group, 2019 to 2034
Figure 128: Western Europe Market Volume (Number of Doses) Analysis by Age Group, 2019 to 2034
Figure 129: Western Europe Market Value Share (%) and BPS Analysis by Age Group, 2024 to 2034
Figure 130: Western Europe Market Y-o-Y Growth (%) Projections by Age Group, 2024 to 2034
Figure 131: Western Europe Market Value (US$ Million) Analysis by Serotype, 2019 to 2034
Figure 132: Western Europe Market Volume (Number of Doses) Analysis by Serotype, 2019 to 2034
Figure 133: Western Europe Market Value Share (%) and BPS Analysis by Serotype, 2024 to 2034
Figure 134: Western Europe Market Y-o-Y Growth (%) Projections by Serotype, 2024 to 2034
Figure 135: Western Europe Market Value (US$ Million) Analysis by End-User, 2019 to 2034
Figure 136: Western Europe Market Volume (Number of Doses) Analysis by End-User, 2019 to 2034
Figure 137: Western Europe Market Value Share (%) and BPS Analysis by End-User, 2024 to 2034
Figure 138: Western Europe Market Y-o-Y Growth (%) Projections by End-User, 2024 to 2034
Figure 139: Western Europe Market Attractiveness by Type, 2024 to 2034
Figure 140: Western Europe Market Attractiveness by Brand, 2024 to 2034
Figure 141: Western Europe Market Attractiveness by Age Group, 2024 to 2034
Figure 142: Western Europe Market Attractiveness by Serotype, 2024 to 2034
Figure 143: Western Europe Market Attractiveness by End-User, 2024 to 2034
Figure 144: Western Europe Market Attractiveness by Country, 2024 to 2034
Figure 145: Eastern Europe Market Value (US$ Million) by Type, 2024 to 2034
Figure 146: Eastern Europe Market Value (US$ Million) by Brand, 2024 to 2034
Figure 147: Eastern Europe Market Value (US$ Million) by Age Group, 2024 to 2034
Figure 148: Eastern Europe Market Value (US$ Million) by Serotype, 2024 to 2034
Figure 149: Eastern Europe Market Value (US$ Million) by End-User, 2024 to 2034
Figure 150: Eastern Europe Market Value (US$ Million) by Country, 2024 to 2034
Figure 151: Eastern Europe Market Value (US$ Million) Analysis by Country, 2019 to 2034
Figure 152: Eastern Europe Market Volume (Number of Doses) Analysis by Country, 2019 to 2034
Figure 153: Eastern Europe Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 154: Eastern Europe Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 155: Eastern Europe Market Value (US$ Million) Analysis by Type, 2019 to 2034
Figure 156: Eastern Europe Market Volume (Number of Doses) Analysis by Type, 2019 to 2034
Figure 157: Eastern Europe Market Value Share (%) and BPS Analysis by Type, 2024 to 2034
Figure 158: Eastern Europe Market Y-o-Y Growth (%) Projections by Type, 2024 to 2034
Figure 159: Eastern Europe Market Value (US$ Million) Analysis by Brand, 2019 to 2034
Figure 160: Eastern Europe Market Volume (Number of Doses) Analysis by Brand, 2019 to 2034
Figure 161: Eastern Europe Market Value Share (%) and BPS Analysis by Brand, 2024 to 2034
Figure 162: Eastern Europe Market Y-o-Y Growth (%) Projections by Brand, 2024 to 2034
Figure 163: Eastern Europe Market Value (US$ Million) Analysis by Age Group, 2019 to 2034
Figure 164: Eastern Europe Market Volume (Number of Doses) Analysis by Age Group, 2019 to 2034
Figure 165: Eastern Europe Market Value Share (%) and BPS Analysis by Age Group, 2024 to 2034
Figure 166: Eastern Europe Market Y-o-Y Growth (%) Projections by Age Group, 2024 to 2034
Figure 167: Eastern Europe Market Value (US$ Million) Analysis by Serotype, 2019 to 2034
Figure 168: Eastern Europe Market Volume (Number of Doses) Analysis by Serotype, 2019 to 2034
Figure 169: Eastern Europe Market Value Share (%) and BPS Analysis by Serotype, 2024 to 2034
Figure 170: Eastern Europe Market Y-o-Y Growth (%) Projections by Serotype, 2024 to 2034
Figure 171: Eastern Europe Market Value (US$ Million) Analysis by End-User, 2019 to 2034
Figure 172: Eastern Europe Market Volume (Number of Doses) Analysis by End-User, 2019 to 2034
Figure 173: Eastern Europe Market Value Share (%) and BPS Analysis by End-User, 2024 to 2034
Figure 174: Eastern Europe Market Y-o-Y Growth (%) Projections by End-User, 2024 to 2034
Figure 175: Eastern Europe Market Attractiveness by Type, 2024 to 2034
Figure 176: Eastern Europe Market Attractiveness by Brand, 2024 to 2034
Figure 177: Eastern Europe Market Attractiveness by Age Group, 2024 to 2034
Figure 178: Eastern Europe Market Attractiveness by Serotype, 2024 to 2034
Figure 179: Eastern Europe Market Attractiveness by End-User, 2024 to 2034
Figure 180: Eastern Europe Market Attractiveness by Country, 2024 to 2034
Figure 181: South Asia and Pacific Market Value (US$ Million) by Type, 2024 to 2034
Figure 182: South Asia and Pacific Market Value (US$ Million) by Brand, 2024 to 2034
Figure 183: South Asia and Pacific Market Value (US$ Million) by Age Group, 2024 to 2034
Figure 184: South Asia and Pacific Market Value (US$ Million) by Serotype, 2024 to 2034
Figure 185: South Asia and Pacific Market Value (US$ Million) by End-User, 2024 to 2034
Figure 186: South Asia and Pacific Market Value (US$ Million) by Country, 2024 to 2034
Figure 187: South Asia and Pacific Market Value (US$ Million) Analysis by Country, 2019 to 2034
Figure 188: South Asia and Pacific Market Volume (Number of Doses) Analysis by Country, 2019 to 2034
Figure 189: South Asia and Pacific Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 190: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 191: South Asia and Pacific Market Value (US$ Million) Analysis by Type, 2019 to 2034
Figure 192: South Asia and Pacific Market Volume (Number of Doses) Analysis by Type, 2019 to 2034
Figure 193: South Asia and Pacific Market Value Share (%) and BPS Analysis by Type, 2024 to 2034
Figure 194: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Type, 2024 to 2034
Figure 195: South Asia and Pacific Market Value (US$ Million) Analysis by Brand, 2019 to 2034
Figure 196: South Asia and Pacific Market Volume (Number of Doses) Analysis by Brand, 2019 to 2034
Figure 197: South Asia and Pacific Market Value Share (%) and BPS Analysis by Brand, 2024 to 2034
Figure 198: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Brand, 2024 to 2034
Figure 199: South Asia and Pacific Market Value (US$ Million) Analysis by Age Group, 2019 to 2034
Figure 200: South Asia and Pacific Market Volume (Number of Doses) Analysis by Age Group, 2019 to 2034
Figure 201: South Asia and Pacific Market Value Share (%) and BPS Analysis by Age Group, 2024 to 2034
Figure 202: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Age Group, 2024 to 2034
Figure 203: South Asia and Pacific Market Value (US$ Million) Analysis by Serotype, 2019 to 2034
Figure 204: South Asia and Pacific Market Volume (Number of Doses) Analysis by Serotype, 2019 to 2034
Figure 205: South Asia and Pacific Market Value Share (%) and BPS Analysis by Serotype, 2024 to 2034
Figure 206: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Serotype, 2024 to 2034
Figure 207: South Asia and Pacific Market Value (US$ Million) Analysis by End-User, 2019 to 2034
Figure 208: South Asia and Pacific Market Volume (Number of Doses) Analysis by End-User, 2019 to 2034
Figure 209: South Asia and Pacific Market Value Share (%) and BPS Analysis by End-User, 2024 to 2034
Figure 210: South Asia and Pacific Market Y-o-Y Growth (%) Projections by End-User, 2024 to 2034
Figure 211: South Asia and Pacific Market Attractiveness by Type, 2024 to 2034
Figure 212: South Asia and Pacific Market Attractiveness by Brand, 2024 to 2034
Figure 213: South Asia and Pacific Market Attractiveness by Age Group, 2024 to 2034
Figure 214: South Asia and Pacific Market Attractiveness by Serotype, 2024 to 2034
Figure 215: South Asia and Pacific Market Attractiveness by End-User, 2024 to 2034
Figure 216: South Asia and Pacific Market Attractiveness by Country, 2024 to 2034
Figure 217: East Asia Market Value (US$ Million) by Type, 2024 to 2034
Figure 218: East Asia Market Value (US$ Million) by Brand, 2024 to 2034
Figure 219: East Asia Market Value (US$ Million) by Age Group, 2024 to 2034
Figure 220: East Asia Market Value (US$ Million) by Serotype, 2024 to 2034
Figure 221: East Asia Market Value (US$ Million) by End-User, 2024 to 2034
Figure 222: East Asia Market Value (US$ Million) by Country, 2024 to 2034
Figure 223: East Asia Market Value (US$ Million) Analysis by Country, 2019 to 2034
Figure 224: East Asia Market Volume (Number of Doses) Analysis by Country, 2019 to 2034
Figure 225: East Asia Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 226: East Asia Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 227: East Asia Market Value (US$ Million) Analysis by Type, 2019 to 2034
Figure 228: East Asia Market Volume (Number of Doses) Analysis by Type, 2019 to 2034
Figure 229: East Asia Market Value Share (%) and BPS Analysis by Type, 2024 to 2034
Figure 230: East Asia Market Y-o-Y Growth (%) Projections by Type, 2024 to 2034
Figure 231: East Asia Market Value (US$ Million) Analysis by Brand, 2019 to 2034
Figure 232: East Asia Market Volume (Number of Doses) Analysis by Brand, 2019 to 2034
Figure 233: East Asia Market Value Share (%) and BPS Analysis by Brand, 2024 to 2034
Figure 234: East Asia Market Y-o-Y Growth (%) Projections by Brand, 2024 to 2034
Figure 235: East Asia Market Value (US$ Million) Analysis by Age Group, 2019 to 2034
Figure 236: East Asia Market Volume (Number of Doses) Analysis by Age Group, 2019 to 2034
Figure 237: East Asia Market Value Share (%) and BPS Analysis by Age Group, 2024 to 2034
Figure 238: East Asia Market Y-o-Y Growth (%) Projections by Age Group, 2024 to 2034
Figure 239: East Asia Market Value (US$ Million) Analysis by Serotype, 2019 to 2034
Figure 240: East Asia Market Volume (Number of Doses) Analysis by Serotype, 2019 to 2034
Figure 241: East Asia Market Value Share (%) and BPS Analysis by Serotype, 2024 to 2034
Figure 242: East Asia Market Y-o-Y Growth (%) Projections by Serotype, 2024 to 2034
Figure 243: East Asia Market Value (US$ Million) Analysis by End-User, 2019 to 2034
Figure 244: East Asia Market Volume (Number of Doses) Analysis by End-User, 2019 to 2034
Figure 245: East Asia Market Value Share (%) and BPS Analysis by End-User, 2024 to 2034
Figure 246: East Asia Market Y-o-Y Growth (%) Projections by End-User, 2024 to 2034
Figure 247: East Asia Market Attractiveness by Type, 2024 to 2034
Figure 248: East Asia Market Attractiveness by Brand, 2024 to 2034
Figure 249: East Asia Market Attractiveness by Age Group, 2024 to 2034
Figure 250: East Asia Market Attractiveness by Serotype, 2024 to 2034
Figure 251: East Asia Market Attractiveness by End-User, 2024 to 2034
Figure 252: East Asia Market Attractiveness by Country, 2024 to 2034
Figure 253: Middle East and Africa Market Value (US$ Million) by Type, 2024 to 2034
Figure 254: Middle East and Africa Market Value (US$ Million) by Brand, 2024 to 2034
Figure 255: Middle East and Africa Market Value (US$ Million) by Age Group, 2024 to 2034
Figure 256: Middle East and Africa Market Value (US$ Million) by Serotype, 2024 to 2034
Figure 257: Middle East and Africa Market Value (US$ Million) by End-User, 2024 to 2034
Figure 258: Middle East and Africa Market Value (US$ Million) by Country, 2024 to 2034
Figure 259: Middle East and Africa Market Value (US$ Million) Analysis by Country, 2019 to 2034
Figure 260: Middle East and Africa Market Volume (Number of Doses) Analysis by Country, 2019 to 2034
Figure 261: Middle East and Africa Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 262: Middle East and Africa Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 263: Middle East and Africa Market Value (US$ Million) Analysis by Type, 2019 to 2034
Figure 264: Middle East and Africa Market Volume (Number of Doses) Analysis by Type, 2019 to 2034
Figure 265: Middle East and Africa Market Value Share (%) and BPS Analysis by Type, 2024 to 2034
Figure 266: Middle East and Africa Market Y-o-Y Growth (%) Projections by Type, 2024 to 2034
Figure 267: Middle East and Africa Market Value (US$ Million) Analysis by Brand, 2019 to 2034
Figure 268: Middle East and Africa Market Volume (Number of Doses) Analysis by Brand, 2019 to 2034
Figure 269: Middle East and Africa Market Value Share (%) and BPS Analysis by Brand, 2024 to 2034
Figure 270: Middle East and Africa Market Y-o-Y Growth (%) Projections by Brand, 2024 to 2034
Figure 271: Middle East and Africa Market Value (US$ Million) Analysis by Age Group, 2019 to 2034
Figure 272: Middle East and Africa Market Volume (Number of Doses) Analysis by Age Group, 2019 to 2034
Figure 273: Middle East and Africa Market Value Share (%) and BPS Analysis by Age Group, 2024 to 2034
Figure 274: Middle East and Africa Market Y-o-Y Growth (%) Projections by Age Group, 2024 to 2034
Figure 275: Middle East and Africa Market Value (US$ Million) Analysis by Serotype, 2019 to 2034
Figure 276: Middle East and Africa Market Volume (Number of Doses) Analysis by Serotype, 2019 to 2034
Figure 277: Middle East and Africa Market Value Share (%) and BPS Analysis by Serotype, 2024 to 2034
Figure 278: Middle East and Africa Market Y-o-Y Growth (%) Projections by Serotype, 2024 to 2034
Figure 279: Middle East and Africa Market Value (US$ Million) Analysis by End-User, 2019 to 2034
Figure 280: Middle East and Africa Market Volume (Number of Doses) Analysis by End-User, 2019 to 2034
Figure 281: Middle East and Africa Market Value Share (%) and BPS Analysis by End-User, 2024 to 2034
Figure 282: Middle East and Africa Market Y-o-Y Growth (%) Projections by End-User, 2024 to 2034
Figure 283: Middle East and Africa Market Attractiveness by Type, 2024 to 2034
Figure 284: Middle East and Africa Market Attractiveness by Brand, 2024 to 2034
Figure 285: Middle East and Africa Market Attractiveness by Age Group, 2024 to 2034
Figure 286: Middle East and Africa Market Attractiveness by Serotype, 2024 to 2034
Figure 287: Middle East and Africa Market Attractiveness by End-User, 2024 to 2034
Figure 288: Middle East and Africa Market Attractiveness by Country, 2024 to 2034
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
What was the Value of the Meningococcal Vaccine Market in 2019?
The global meningococcal vaccine market was worth US$ 2,433.8 million in 2019.
What is the Sales Outlook for Meningococcal Vaccines in 2024?
The sales outlook for meningococcal vaccines is likely to be valued at US$ 4,049.1 million in 2024.
What is the Demand Forecast for Meningococcal Vaccines by 2034?
The demand for meningococcal vaccines is projected to reach a market value of US$ 10,788.0 million by the end of 2034.
What is the Adoption Projection for Meningococcal Vaccines?
The adoption of meningococcal vaccines is projected to rise at a CAGR of 10.3% through 2034.
At What Rate is the North American Market Predicted to Grow?
The North American market for meningococcal vaccines is forecasted to expand at a CAGR of 11.1% through 2034.
Meningococcal Vaccine Market